Samsung Bioepis has responded to Alexion’s efforts to block the sale of a biosimilar version of a blood treatment drug, asserting in court that its product does not violate the patent protections held by an AstraZeneca subsidiary. This legal challenge highlights ongoing disputes in the pharmaceutical industry regarding biosimilars and patent rights. For further details, you can read more here.